Stock Analysis on Net
Stock Analysis on Net

Celgene Corp. (NASDAQ:CELG)

This company has been moved to the archive! The financial data has not been updated since October 31, 2019.

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Celgene Corp., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

Microsoft Excel
Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015 Dec 31, 2014 Sep 30, 2014 Jun 30, 2014 Mar 31, 2014
Short-term borrowings and current portion of long-term debt 1,498 — 500 501 502 1,497 — — 1,400 500 500 501 501 — — — 1,200 1,363 504 606 100 192 870
Accounts payable 421 327 340 418 292 294 320 305 263 272 240 247 235 230 220 241 189 205 204 198 197 185 149
Accrued expenses and other current liabilities 2,964 3,035 2,975 2,987 2,705 2,615 2,672 2,523 2,265 2,379 1,808 2,115 1,847 1,696 1,542 1,648 1,674 1,323 1,347 1,267 1,053 1,066 1,358
Income taxes payable 82 280 72 78 105 32 54 84 55 32 25 41 4 13 15 20 6 11 13 13 15 16 17
Current portion of deferred revenue 44 43 68 73 79 64 69 75 66 57 56 55 62 49 58 61 75 58 29 29 34 34 31
Current liabilities 5,009 3,685 3,955 4,057 3,683 4,502 3,115 2,987 4,049 3,240 2,629 2,959 2,649 1,987 1,834 1,969 3,144 2,960 2,097 2,112 1,398 1,492 2,425
Deferred revenue, net of current portion 16 40 76 73 74 63 35 34 46 31 29 28 28 28 29 30 29 30 27 28 28 28 25
Income taxes payable 2,454 2,256 2,232 2,190 2,451 2,368 2,514 2,490 469 463 441 420 370 346 327 324 323 307 288 273 264 259 245
Deferred income tax liabilities 2,854 2,676 2,714 2,753 2,811 2,771 2,777 1,327 — — — — — — — — — — — — — — —
Other non-current tax liabilities — — — — — — — — 2,519 2,519 2,519 2,519 2,519 2,519 2,519 2,519 — — — — — — —
Other non-current liabilities 654 685 716 477 594 556 672 544 1,929 1,825 1,774 1,771 1,734 1,821 1,912 2,042 4,200 1,872 2,000 2,137 2,208 2,229 1,300
Long-term debt, net of discount, excluding current portion 18,289 19,790 19,781 19,769 19,742 19,754 20,271 15,838 12,874 13,783 13,784 13,789 13,803 14,312 14,268 14,250 14,298 6,256 6,303 6,266 6,737 6,743 4,224
Non-current liabilities 24,267 25,447 25,519 25,262 25,672 25,512 26,269 20,233 17,837 18,621 18,547 18,527 18,454 19,026 19,055 19,166 18,850 8,464 8,618 8,703 9,237 9,259 5,795
Total liabilities 29,276 29,132 29,474 29,319 29,355 30,014 29,384 23,220 21,886 21,861 21,176 21,486 21,103 21,013 20,889 21,134 21,994 11,424 10,716 10,815 10,635 10,751 8,220
Preferred stock, $.01 par value per share; none outstanding — — — — — — — — — — — — — — — — — — — — — — —
Common stock, $.01 par value per share 10 10 10 10 10 10 10 10 10 10 10 10 10 10 9 9 9 9 9 9 9 9 5
Common stock in treasury, at cost (26,334) (26,331) (26,298) (26,336) (26,315) (25,700) (22,946) (20,243) (17,243) (17,069) (16,557) (16,281) (16,130) (15,851) (15,432) (14,052) (13,613) (12,789) (11,804) (10,699) (10,092) (9,837) (9,319)
Additional paid-in capital 16,072 15,753 15,381 14,978 14,756 13,835 14,077 13,806 13,604 13,174 12,749 12,378 11,981 11,666 11,370 11,119 10,827 10,496 10,186 9,827 9,440 9,166 8,907
Retained earnings 22,366 20,675 19,104 17,559 16,486 15,404 14,359 13,061 13,142 12,093 11,032 10,074 9,645 9,473 8,875 8,074 7,513 7,548 7,191 6,472 5,859 5,350 4,752
Accumulated other comprehensive income (loss) (27) (56) (32) (50) (77) (119) (328) 287 337 237 410 419 145 251 252 768 639 1,058 1,182 915 553 164 140
Stockholders’ equity 12,087 10,051 8,165 6,161 4,860 3,430 5,172 6,921 9,850 8,445 7,644 6,599 5,650 5,549 5,075 5,919 5,376 6,322 6,765 6,525 5,768 4,851 4,485
Total liabilities and stockholders’ equity 41,363 39,183 37,639 35,480 34,215 33,444 34,556 30,141 31,736 30,306 28,820 28,086 26,754 26,562 25,964 27,053 27,369 17,746 17,481 17,340 16,403 15,602 12,705

Based on: 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-31), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-06-30), 10-Q (reporting date: 2018-03-31), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-09-30), 10-Q (reporting date: 2017-06-30), 10-Q (reporting date: 2017-03-31), 10-K (reporting date: 2016-12-31), 10-Q (reporting date: 2016-09-30), 10-Q (reporting date: 2016-06-30), 10-Q (reporting date: 2016-03-31), 10-K (reporting date: 2015-12-31), 10-Q (reporting date: 2015-09-30), 10-Q (reporting date: 2015-06-30), 10-Q (reporting date: 2015-03-31), 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Celgene Corp. current liabilities decreased from Q1 2019 to Q2 2019 but then increased from Q2 2019 to Q3 2019 exceeding Q1 2019 level.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Celgene Corp. non-current liabilities decreased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Celgene Corp. total liabilities decreased from Q1 2019 to Q2 2019 but then slightly increased from Q2 2019 to Q3 2019.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Celgene Corp. stockholders’ equity increased from Q1 2019 to Q2 2019 and from Q2 2019 to Q3 2019.